Private Label Tranexamic Acid SPF 30 Face Cream Low MOQ

The minimum order quantity for a private label tranexamic acid SPF 30 face cream depends heavily on whether the product is classified as a cosmetic or an OTC drug, and on the scale of the contract manufacturer you work with. In the United States, any face cream carrying an SPF 30 claim is regulated as an OTC drug under FDA rules. OTC drug manufacturing requires pharmaceutical-grade GMP facilities operating under 21 CFR Part 211, which means the universe of eligible manufacturers is smaller than for a purely cosmetic product. Smaller, specialty OTC co-manufacturers — many of which focus on prestige skincare and indie brands — typically set MOQs between 100 and 500 units per SKU. Mid-tier facilities that serve emerging brands scaling toward retail commonly set floors between 500 and 2,000 units. Large-scale co-manufacturers with national retail clients rarely take orders below 5,000 units. Several factors push MOQs up or down. If you use the manufacturer's existing stock base formula and only need label customization, MOQs can stay near the low end. If you need a custom formula — for example, a specific tranexamic acid percentage, a novel UV filter blend, or a proprietary fragrance — the manufacturer must conduct additional stability and compatibility work, which many recoup through a higher MOQ or a formulation development fee ($2,000–$10,000 range). Packaging choice also matters: a bespoke glass jar with custom mold tooling may carry its own packaging MOQ of 5,000–10,000 units, making packaging the binding constraint rather than the filling run. For founders launching a proof-of-concept or DTC-first brand, targeting manufacturers with 100–300 unit MOQs is realistic, though unit costs will be higher ($8–$18 per unit ex-works for a 50 mL jar) and turnaround for small runs can sometimes be slower if the facility prioritizes larger clients. The AJ Cosmo Labs iOS app lets you filter supplier listings by MOQ before you ever send a cold email, which saves weeks of back-and-forth with facilities that aren't the right size fit. One common mistake first-timers make is quoting MOQ to a manufacturer before asking whether they are FDA-registered as an OTC drug facility. A manufacturer might offer 200-unit MOQs but only hold cosmetic GMP certification — meaning they legally cannot fill a product with an SPF claim in the US. Always verify the FDA establishment registration number first.

The total cost to private label a tranexamic acid SPF 30 face cream has four distinct buckets: formulation and development, regulatory testing, packaging, and manufacturing fill. Founders who only budget for the fill cost routinely run out of runway before their product ships. Formulation and development fees range from $0 to $15,000 depending on how much customization you need. If you use a manufacturer's existing TXA SPF base formula and only change the fragrance, preservative, or texture modifier, some manufacturers waive the development fee entirely or charge $500–$2,000. A fully custom formula with a specific TXA percentage, a chosen UV filter stack, and a proprietary sensory profile costs $5,000–$15,000 in formulation fees and adds 4–8 weeks to your timeline before stability testing even begins. Regulatory testing is non-negotiable for SPF products in the US. SPF efficacy testing at an ISO 17025-accredited lab costs $3,000–$8,000 per formula. Broad-spectrum (critical wavelength) testing typically runs $500–$1,500 and is often bundled with SPF testing. Accelerated stability testing — required to substantiate a 24-month shelf life — costs $1,500–$4,000 and takes a minimum of 70 days for a 12-month equivalence read, or about 6 months for a full 24-month equivalence study. A regulatory consultant to draft your Drug Facts label, INCI list, and claims review typically charges $1,500–$5,000 for a single SKU. Packaging costs depend on format. A stock white HDPE pump bottle runs $0.30–$0.80 per unit. A stock glass jar with an aluminum lid runs $0.80–$2.00 per unit. Custom-molded packaging requires tooling investment of $8,000–$30,000 amortized across the production run, so it only makes economic sense above roughly 10,000 units. Manufacturing fill cost — the actual labor and materials to mix and fill the product — ranges from $2 to $18 per unit depending on batch size and the tranexamic acid input cost. Pharmaceutical-grade tranexamic acid runs approximately $40–$80 per kilogram; at 3% inclusion in a 50 mL cream (roughly 1.5 g per unit), raw material cost for TXA alone is about $0.08–$0.12 per unit at scale, though small-batch purchasing increases this. A realistic all-in budget for a first run of 500 units of private label TXA SPF 30 face cream in a stock package is $20,000–$45,000. At 5,000 units with custom packaging and full regulatory package, budget $60,000–$120,000. AJ Cosmo Labs helps founders compare itemized quotes from multiple manufacturers so there are no hidden cost surprises after signing a contract.

The end-to-end timeline from signing a manufacturing agreement to receiving sellable, labeled product is typically 12–20 weeks for a private label tranexamic acid SPF 30 face cream. The exact duration is driven by four stages: formulation and stability screening, regulatory testing, packaging procurement, and the fill-and-finish run itself. Formulation and stability screening takes 3–6 weeks if you're adapting an existing base formula. If the manufacturer needs to develop a new formula from scratch — for example, to hit a specific TXA percentage or to combine TXA with niacinamide or kojic acid as co-brighteners — add another 4–8 weeks for prototype iterations and early compatibility checks between the TXA and the UV filter system. SPF regulatory testing is the single biggest wildcard. An accredited SPF testing lab typically has a 4–8 week queue, plus 1–2 weeks for the actual test protocol. If your formula fails the SPF 30 threshold on the first run — which happens when the UV filter concentrations are borderline — you face a reformulation cycle and a retest, adding another 6–10 weeks. Experienced manufacturers with active SPF testing relationships can sometimes get faster slots, so this vetting question is worth asking upfront. Packaging procurement is often the item that catches founders off guard. Stock packaging (off-the-shelf bottles, jars, pumps, boxes) typically has a 3–5 week lead time from a domestic distributor or 8–14 weeks from overseas. Custom-molded packaging can run 16–24 weeks just for tooling and sampling. If your packaging isn't ordered before or concurrent with your formula finalization, it becomes the critical path item that delays your launch by months. The actual fill-and-finish manufacturing run — mixing the bulk batch, filling into containers, applying labels, and packing for shipment — takes 1–3 weeks for a run of 500–5,000 units once the manufacturer has approved raw materials on hand and your packaging has arrived at their dock. A common mistake is treating these stages as sequential rather than parallel. Founders who wait for SPF test results before ordering packaging lose 6–10 weeks unnecessarily. Savvy brand founders use the AJ Cosmo Labs app to stay organized: tracking samples, logging lab results, and coordinating packaging timelines in one place so every workstream runs in parallel where possible.

Tranexamic acid (TXA) in topical face creams is most commonly formulated at concentrations between 2% and 5% by weight. This range is supported by the bulk of published dermatological literature and mirrors the concentration used in clinical studies showing statistically significant reduction in melasma severity scores (MASI scores) compared to vehicle control. The landmark 2012 study by Kanechorn Na Ayuthaya and colleagues showed that a 3% topical tranexamic acid solution applied twice daily produced meaningful improvement in melasma over 12 weeks. Subsequent split-face studies comparing 2% TXA with kojic acid and 4% hydroquinone found TXA to be comparably effective with a better tolerability profile — important for consumers who have experienced irritation from hydroquinone-based brighteners. From a formulation chemistry standpoint, TXA is water-soluble, which makes it relatively straightforward to incorporate into the aqueous phase of an oil-in-water emulsion. However, a few technical considerations affect the target concentration in a private label product. First, TXA can shift the pH of the emulsion system — cosmetic chemists typically target a finished cream pH of 5.5–6.5 for both skin compatibility and preservative efficacy; TXA tends to push pH upward and may require buffering with citric acid or lactic acid. Second, TXA interacts with some cationic emulsifiers, causing instability — formulators working with TXA at 3–5% should confirm compatibility with their chosen emulsifier system through accelerated stability testing at 45°C for a minimum of 8 weeks before committing to a production batch. For a product also carrying an SPF 30 claim, the cosmetic chemist must further verify that the TXA doesn't degrade UV filter performance over time. Some chemical filters (particularly avobenzone) are photolabile, and the interaction with TXA in an emulsion matrix should be validated through photostability testing per ISO 24443. Most private label manufacturers offering a TXA SPF 30 base formula have already conducted this compatibility work at a fixed concentration — commonly 2% or 3% — and can share their stability dataset on request. If you need 5% TXA specifically for a clinical-positioned product, expect a custom formulation fee and additional stability testing time. AJ Cosmo Labs supplier profiles let you filter for manufacturers who already hold validated TXA base formulas, reducing your time-to-market significantly.

A product sold in the United States that bears an SPF claim — including an SPF 30 face cream containing tranexamic acid — is regulated as an over-the-counter (OTC) drug by the FDA, not as a cosmetic. This is a critical distinction that affects everything from the manufacturing facility you can use to the label copy you are permitted to print. Under the FDA's OTC Drug Review framework, sunscreen active ingredients and their maximum permitted concentrations are governed by the OTC Sunscreen Monograph, codified in 21 CFR Part 352 and updated through the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020. A product that uses only monograph-approved UV filters (such as avobenzone up to 3%, homosalate up to 15%, octinoxate up to 7.5%, zinc oxide up to 25%, or titanium dioxide up to 25%) at permitted levels, and that complies with all labeling and testing requirements, does not need pre-market approval from the FDA — it is what regulators call a "monograph-compliant" OTC product. This means you can bring it to market without filing a New Drug Application (NDA), which would take years. However, "no pre-market approval" does not mean "no requirements." The following are mandatory and enforceable: SPF value substantiation through standardized testing (FDA method or ISO 24444 with demonstrated equivalence); broad-spectrum substantiation through critical wavelength testing; labeling that includes a Drug Facts panel with active ingredients (UV filters and their percentages), directions for use, warnings (including the skin cancer prevention language required by the 2019 Sunscreen Final Rule), and inactive ingredients in INCI order; and manufacture in a facility registered with the FDA as an OTC drug manufacturer and inspected under 21 CFR Part 211 pharmaceutical GMP standards. Transexamic acid itself, as the brightening active, is not an FDA-regulated drug ingredient in this context — it is treated as an inactive ingredient in the finished OTC drug product. This means it does not trigger additional drug review, but it cannot be called out in the Drug Facts active ingredient section; it appears in the inactive ingredient list. One mistake first-time founders make is placing an order with a contract manufacturer that holds only cosmetic GMP (ISO 22716) certification and assuming that is sufficient for an SPF product. It is not. If the FDA inspects an SPF product manufactured in a non-pharmaceutical GMP facility, the product is subject to seizure. Always confirm FDA OTC drug facility registration before signing. The AJ Cosmo Labs iOS app surfaces OTC-drug-capable manufacturers separately from cosmetics-only facilities, which removes this risk from the supplier-vetting process.

Yes, but the regulatory framework is entirely different from the United States, and a formula compliant for US sale may require meaningful reformulation before it can legally enter EU or UK markets. In the European Union, SPF products are regulated as cosmetics under Regulation (EC) No 1223/2009, not as drugs. This is the opposite of the US approach. There is no "OTC drug" category for sunscreens in Europe; SPF is treated as a cosmetic claim, and UV filters are governed by Annex VI of the EU Cosmetics Regulation. The approved UV filter list under Annex VI differs significantly from the FDA's OTC Monograph list. For example, bemotrizinol (Tinosorb S) and bisoctrizole (Tinosorb M) are permitted in Europe but are not on the FDA monograph — and conversely, some US-common filters like oxybenzone face restrictions in certain EU member states. If your US formula uses filter combinations not on Annex VI, you must reformulate for European distribution. For EU market access, your product must also undergo a Cosmetic Product Safety Assessment (CPSA) performed by a qualified Person Responsible (PR) — a toxicologist or similarly credentialed professional — and the product must be notified in the CPNP (Cosmetic Products Notification Portal) before it goes on sale in any EU member state. The safety assessment typically costs €800–€3,000 per product and takes 4–8 weeks depending on the assessor's queue. Post-Brexit, the United Kingdom operates its own cosmetics regulation (UK Cosmetics Regulation, retained from EU law) and requires a UK Responsible Person and notification on the SCPN (UK's equivalent of CPNP). If you're selling in both EU and UK, you need a separate RP and notification in each jurisdiction. Transexamic acid itself is not a restricted ingredient in either EU or UK cosmetics regulations as of 2024, and there are no concentration limits specifically for TXA in the EU Cosmetics Regulation Annexes at the concentrations typically used in face creams (2–5%). However, your safety assessor will review TXA at the intended concentration as part of the CPSA and will flag any concerns. Founders targeting both US and EU markets often develop two formula variants from the same manufacturer — one with an FDA-monograph-compliant filter system and one with an EU Annex VI-compliant filter system — sharing the same TXA brightening base. This approach minimizes development cost while achieving dual-market compliance. AJ Cosmo Labs can connect you with cosmetic chemists and contract manufacturers experienced in multi-market SPF compliance, which is a specialized subset of the broader cosmetic manufacturing community.

Finding a low-MOQ manufacturer for a private label tranexamic acid SPF 30 face cream requires more precision than a general Google search or trade show visit, because you need a supplier who simultaneously meets three criteria that most directories don't filter for: OTC drug manufacturing capability, demonstrated TXA formulation experience, and willingness to run small batches. The traditional approach — searching trade directories, attending Cosmoprof or NYSCC Suppliers' Day, cold-emailing co-manufacturers — works but is slow. Expect 4–8 weeks of outreach before you have 3–5 qualified proposals in hand. Many manufacturers listed in generic directories hold only cosmetic GMP and cannot legally fill an SPF product for US sale. Others have a 5,000-unit floor that is incompatible with a first launch. Filtering for the combination of OTC drug capability plus low MOQ plus TXA experience by manual research can take months. A faster path is using AJ Cosmo Labs, where you post a structured product brief — specifying your target TXA percentage, SPF level, packaging format, target MOQ, and market (US, EU, or both) — and receive responses only from manufacturers who match your requirements. The iOS app's supplier profiles include facility certification data, MOQ floors, and industry specializations, so you can filter before you ever message a supplier. When evaluating any manufacturer, regardless of how you found them, ask for the following before signing an NDA or development agreement: their FDA OTC drug facility registration number (look it up on the FDA's public FEI database to verify); a reference list of brands they've produced TXA-containing products for; a sample stability data packet for an existing TXA emulsion (accelerated at 45°C for 8 weeks minimum); their preferred SPF testing lab partner and average queue time; and a fully itemized quote that separates development fees, testing fees, raw material costs, packaging, and filling costs so you can compare apples to apples across multiple bids. The most common mistake founders make when sourcing this specific product type is choosing a manufacturer based on price per unit alone, without confirming OTC drug GMP status. A $3/unit fill cost at a non-registered facility produces a product you legally cannot sell in the US with an SPF claim. The second most common mistake is not locking packaging lead times in parallel with formula development, resulting in a ready formula sitting on the manufacturer's shelf for 10–14 weeks waiting for bottles to arrive. Using AJ Cosmo Labs's escrow-based milestone payment system also protects you financially: rather than wiring a large deposit to an unfamiliar manufacturer, you fund milestones that release only when the manufacturer delivers — formula prototype received, stability initiated, SPF test submitted, bulk approved. This is especially valuable when working with a new partner on a complex dual-active product like a TXA SPF 30 cream.